Smokers Who Quit Before Age 45 Significantly Reduce Risk of Lung Cancer

Industry Insight
Jun.09.2022
Smokers Who Quit Before Age 45 Significantly Reduce Risk of Lung Cancer
A new study conducted by the American Cancer Society highlighted that while quitting smoking reduces cancer risks at any age, doing so before the age of 45 nearly eliminates all risk.

Titled, “Association of Smoking Initiation and Cessation Across the Life Course and Cancer Mortality Prospective Study of 410 000 US Adults,” the study of over 400,000 Americans, found that smokers are three times more likely to die of a tobacco-related cancer than nonsmokers.

 

However, reported the researchers, quitting by age 45 reduces this risk by 89%, while for those who quit before they are 35, the risk is completely eliminated. On the other hand, quitting between ages 45-54 still reduces the risk by a significant 78%, while doing so between ages 55-64 cuts it by 56%.

 

The research team found that similarly, the age of smoking initiation also has an impact on cancer risk. People who started smoking before age 18 had at least three times the risk of dying from cancer, while those who started before age 10 had four times the risk.

 

Tobacco use behavior following a cancer diagnosis

 

Another recent study published in Annals of Internal Medicine, found that quitting smoking following a lung cancer diagnosis may prevent cancer recurrence and extend life. Titled, “Postdiagnosis Smoking Cessation and Reduced Risk for Lung Cancer Progression and Mortality,” the study was conducted by researchers from the International Agency for Research on Cancer, the specialized cancer agency of the World Health Organization, in collaboration with the N.N. Blokhin National Medical Research Centre of Oncology in Russia. The research team recruited 517 current adults who were current smokers when they were diagnosed with early-stage non-small cell lung cancer from 2 sites in Moscow, Russia.

 

At the start of the study the participants were interviewed to determine medical and lifestyle history, including tumor characteristics, and their tobacco use patterns. Each participant was followed each year for an average of 7 years in a bid to record any changes in their smoking behavior.

 

Of 517 lung cancer patients who were smokers when diagnosed, less than half quit (44.5%), and very few relapsed. The patients who quit smoking were more likely to live longer overall (6.6 years vs. 4.8. years), live longer without lung cancer (5.7 vs. 3.9 years) and have their disease progress at a slower rate (7.9 vs. 6 years).

 

In light of these findings, the research team concluded that quitting smoking after being diagnosed with early-stage non-small cell lung cancer may slow disease progression and decrease mortality.

 

Source:VapingPost

Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
AIRSCREAM’s production hub in the Czech Republic brings nicotine pouch manufacturing, e-liquid bottling, product documentation, warehousing and international logistics into one operation, giving brands and commercial partners a practical platform from which to launch, expand and enter new markets.
Market
Sep.16 by 2Firsts Perspectives
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
At InterTabac 2026 in Dortmund, PMI is presenting multiple brands and products along “The PMI Boulevard,” including IQOS, ZYN, VEEV and Marlboro. On-site images captured by 2Firsts show dedicated spaces including the IQOS Boutique, ZYN Café, PMI Gallery and Marlboro Office
Market
Sep.16 by 2Firsts Perspectives
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Asia Manufacturing Corp. has invested ₱2.1 billion, or about $37 million, in its manufacturing site in Malvar, Batangas, Philippines, to expand tobacco-processing capabilities. About ₱1.9 billion is allocated to JTI's first Dry Ice Expanded Tobacco, or DIET, facility in Southeast Asia, while more than ₱177 million has been spent on expanding its Controlled Atmosphere treatment facility. The Batangas plant supplies the Philippine market and exports to 22 overseas markets, making it one of JTI's key manufacturing hubs in Asia.
Sep.24
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
On September 16, 2Firsts hosted a China-focused industry forum during InterTabac in Dortmund, bringing together more than 30 participants from North America, Europe, India, South Korea and other markets. The session covered traditional tobacco, next-generation products, exports, technology, regulation and supply chains, while examining how China’s tobacco sector operates, where its transformation may be heading, and why its growing role matters increasingly to companies across the global tobacco and nicotine industry.
Sep.21
2Firsts On-Site | CTIHK Showcases Nicotine Pouches, Heated Tobacco and Chinese Cigars at InterTabac 2026
2Firsts On-Site | CTIHK Showcases Nicotine Pouches, Heated Tobacco and Chinese Cigars at InterTabac 2026
At InterTabac 2026 in Dortmund, China Tobacco International (HK) Company Limited (CTIHK) is exhibiting across two separate booths in Hall 5 and Hall 4. Products observed by 2Firsts include heated tobacco products, nicotine pouches, Chinese cigars and tobacco leaf. Nicotine pouch products on display include TOOP, Shuangxi and Ashima.
Market
Sep.16
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23